<DOC>
	<DOC>NCT00884286</DOC>
	<brief_summary>This is a multicenter study to assess the anti-tumour activity,to investigate the safety profile and to obtain additional pharmacokinetic information for Aplidin® given as 1-hour weekly IV infusion in patients with aggressive non-Hodgkin's Lymphoma.</brief_summary>
	<brief_title>Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma</brief_title>
	<detailed_description>A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin® As A 1-Hour Weekly IV Infusion, In Patients With Relapsed Or Refractory aggressive non-Hodgkin's Lymphoma. Primary • To assess the anti-tumour activity of Aplidin® given as a 1-hour weekly IV infusion, in patients with aggressive non-Hodgkin's Lymphoma, relapsing or refractory to a prior therapy. Secondary - To further investigate the safety profile of Aplidin® given as 1-hour weekly IV infusion in this patient population. - To obtain additional pharmacokinetic information for Aplidin® given as 1-hour weekly IV infusion in patients with aggressive non-Hodgkin's Lymphoma.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<criteria>Written informed consent Histologically confirmed aggressive lymphomas, Patient requires treatment because NHL relapses Measurable disease Recovery from any nonhematological toxicity derived from previous treatments. The presence of alopecia and NCICTC grade &lt; 2 symptomatic peripheral neuropathy is allowed. Age &gt; 18 years. Performance status (ECOG) &lt; 2 Adequate renal, hepatic, and bone marrow function (assessed &lt; 14 days before inclusion in the study) Left ventricular ejection fraction within normal limits. Prior therapy with Aplidin®. Concomitant therapy with any antilymphoproliferative agent Acute lymphoblastic leukemia. CNS lymphoma. HIVassociated lymphoma. Prior gene therapy with viral vectors. More than three previous lines of systemic biological agents or chemotherapies. Washout periods since the end of the precedent therapy less than: 6 weeks for nitrosourea or high dose chemotherapy 3 weeks for other chemotherapies or biological agents 4 weeks for radiation or radionuclide therapy (6 weeks in case of prior extensive external beam radiation (more than 25% of bone marrow distribution). 4 weeks for major prior surgery 30 days for any investigational product 4 weeks for immunosuppressive therapy after allogeneic hematopoietic stem cell transplantation. Pregnant or lactating women. Men and women of reproductive potential who are not using effective contraceptive methods History of another neoplastic disease. Exceptions: Nonmelanoma skin cancer,cCarcinoma in situ of any site,any other cancer curatively treated and no evidence of disease for at least 10 years. Known cerebral or leptomeningeal involvement. Other relevant diseases or adverse clinical conditions Treatment with any investigational product in the 30 days period before inclusion in the study. Known hypersensitivity to Aplidin®, mannitol, cremophor EL, or ethanol Limitation of the patient's ability to comply with the treatment or followup protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Aplidin</keyword>
	<keyword>Aggressive Non Hodgkin Lymphoma</keyword>
	<keyword>Leukemia-Lymphoma, Adult T-Cell and B-cell</keyword>
</DOC>